RxDoctor Payments Data

Zachary Gertz, MD

Interventional Cardiology · Richmond, VANPI 1457414849

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,635 of the $3,010 with a category attached, or 87.5%. 11 manufacturers reported payments, led by Edwards Lifesciences at 31.5% of the total. That places this record below the midpoint for interventional cardiology clinicians in VA, where the typical reported total is $4,743.

$3,010in general payments, 2019–2025

Across 38 payments — averaging $79.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$947
  • Boston Scientific$751
  • Abbott$498
  • W. L. Gore & Associates, Inc.$375
  • Medtronic$168
  • Philips North America LLC$85
  • plus $186 from 5 others
$32,834in research payments, 2019–2025

Across 21 payments — averaging $1563.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$19K
  • Abbott$14K

What the payments were for

  • Speaking & faculty fees$37512%
  • Food & beverage$2,63588%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,010 in reported general payments places this provider in the 35th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$107,130
Medicare patients
360
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban29$20,708
Metoprolol Succinate19$279
Spironolactone11$68
Pravastatin Sodium12$53
Simvastatin12$22

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →